SeQuent Scientific and Viyash Lifesciences Announce Strategic Merger to Create a Global Animal
Health Leader with End-to-End Integrated Capabilities
The proposed merger is expected to create a unique & differentiated platform with leading
market position in Animal healthcare and integrated capabilities for global pharmaceutical
clients, supported by a strong operating backbone
Combined entity to have access to global markets (150+ countries) with strong R&D, IP and
product development capabilities and 16 state of the art manufacturing facilities
SeQuent Scientific Ltd. (“SeQuent”), a leading player in the global Animal health industry and Viyash
Lifesciences Private Limited (“Viyash”), an integrated global pharmaceutical company, propose a
strategic merger of SeQuent and Viyash, aimed at turbocharging the journey towards creating a unique,
differentiated Animal health leader with end-to-end capabilities. With Viyash’s operating capabilities,
this merger will significantly enhance the combined entity’s scale, deepen its Research & Development
(R&D) capabilities, strengthen its supply chain, and position the combined entity to become a leading
player in the high-growth pharmaceutical markets.
The combined entity will have a more robust financial profile, as reflected in its margin profile & Balance
Sheet. Further, the entity will have a 5x higher R&D talent pool and 9x more USFDA approved
manufacturing facilities, which will form a strong operating backbone to serve its customer better.
Commenting on the proposed merger, Mr. Rajaram Narayanan, Managing Director and CEO of SeQuent
said, “We are thrilled to announce a transformative step in our journey towards creating a unique,
differentiated global leader in Animal health with integrated capabilities. We believe that in order to
continue to deliver differentiated value to our customers in times to come, it is imperative to scale up our
product development and R&D capabilities to capture the market opportunity we are seeing and to build
on our leadership in the Animal health market. To strengthen our end-to-end capabilities, we have decided to pursue an inorganic route, and we propose a potential merger with Viyash Lifesciences. We believe that Viyash has deep capabilities in what we need, headed by a strong management team under Dr. Haribabu.
Together, we will turbocharge our growth engines including capturing the market opportunity in the
overall global pharma markets enabled by Viyash’s capabilities.”
Commenting on the proposed merger, Dr. Haribabu Bodepudi, Chairman and CEO, Viyash, said, “We are
excited to merge forces with SeQuent and create an elevated entity that is uniquely positioned. This merger brings together two complementary businesses that share a commitment to innovation, operational excellence, and delivering world-class solutions for our customers. With our combined resources, R&D capabilities, manufacturing capacities, and streamlined supply chain, we are well-positioned to accelerate growth and offer a wider range of high-quality products to our customers.”
The proposed merger is subject to receipt of customary statutory and regulatory approvals, including
from shareholders, stock exchanges, Competition Commission of India and the National Company Law
Tribunal.
JYOTI